Latigo Biotherapeutics Files for Nasdaq IPO

OWL Blue Owl Capital Inc

$9.07 +1.11%

View chart & analysis →

GS +0.42% JEF -1.92%

1. 1Latigo Biotherapeutics (LTGO), a developer of non-opioid painkillers backed by Blue Owl, has filed for an IPO.
2. 2Its late-stage clinical drug candidate showed roughly 50% greater analgesic efficacy compared with the opioid Vicodin.
3. 3The company plans to conduct a Phase 3 trial this year for moderate-to-severe acute pain, with results expected in the second half of next year, while Goldman Sachs and Jefferies are among the underwriters of the offering.

Source Bloomberg · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →